CJC-1295 DAC 5 mg

Dragon Pharma CJC-1295 DAC – Long-Acting GHRH Peptide

CJC-1295 DAC 5 mg by Dragon Pharma is a long-acting growth hormone-releasing hormone (GHRH) analog studied for its ability to support endogenous growth hormone release over an extended period. In peptide research, CJC-1295 DAC is well known for its sustained activity profile, making it a popular option for recovery, sleep support, and body composition protocols.

Compared with shorter-acting growth hormone peptides, CJC-1295 DAC is often preferred by users who want less frequent dosing while still maintaining steady support for the GH/IGF-1 axis. For users looking to buy CJC-1295 by Dragon Pharma, product quality, storage standards, and source reliability all play an important role.

CJC-1295 DAC Composition

CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone modified with a Drug Affinity Complex (DAC). This modification allows the peptide to bind to albumin in the bloodstream, extending its half-life far beyond that of standard GHRH peptides.

Because of this albumin-binding mechanism, CJC-1295 DAC has become one of the best-known long-acting GH-support peptides in research settings. It is commonly studied for its influence on growth hormone pulses, IGF-1 levels, recovery processes, and body composition changes over time.

Bodybuilding and Performance Support

Among athletes and bodybuilders, CJC-1295 DAC is most often researched for its broad recovery and performance-support profile. Unlike compounds that rely on direct hormone replacement, this peptide is studied for its ability to encourage natural growth hormone release pathways.

• Growth hormone support: researched for sustained endogenous GH release
• Recovery support: often explored in post-training and tissue-repair focused protocols
• Sleep quality: frequently associated with deeper and more restorative sleep patterns
• Body composition: studied for lean-mass support and fat-loss related protocols
• Joint and connective tissue support: commonly researched in longer-term recovery plans
• Less frequent dosing: popular among users who prefer weekly rather than daily peptide schedules

For a clinical overview of its pharmacokinetics and GH response, see this PubMed study on CJC-1295 in healthy volunteers.

Research Background

CJC-1295 was originally investigated for conditions involving reduced growth hormone output and altered body composition. Its main research appeal comes from the DAC technology, which prolongs peptide exposure and helps maintain sustained biologic activity after administration.

This longer activity profile distinguishes it from non-DAC GHRH analogs and makes it especially relevant in studies focused on recovery, GH optimization, and age-related decline in growth hormone signaling.

Dosage (Men)

Note: CJC-1295 DAC is intended for research purposes only. The following reflects common protocol patterns and provided context rather than medical advice.

Because of its long half-life, CJC-1295 DAC is commonly used less frequently than shorter-acting GH peptides. Typical research-oriented protocols may include:

• Standard Protocol: 1-2 mg injected subcutaneously twice weekly
• Higher-Range Protocol: 2-3 mg twice weekly in more advanced research settings
• Maintenance Protocol: 1 mg once weekly after initial use

The 5 mg vial is often reconstituted with 2 mL of bacteriostatic water, creating a concentration of 2.5 mg/mL. At that concentration, a 1 mg dose equals 0.4 mL, or 40 units on a U-100 insulin syringe.

Dosage (Women)

Female research protocols often use lower amounts, frequently in the range of 0.5-1 mg twice weekly, with some protocols using 0.5 mg weekly for maintenance-style applications. As with many peptides, conservative starting doses are often preferred.

Active Life

The defining feature of CJC-1295 DAC is its extended half-life. Due to albumin binding, the peptide remains active far longer than standard GHRH analogs, with biologic effects often discussed across a period of several days. This is why once- or twice-weekly administration is common in research settings.

CJC-1295 DAC Side Effects

CJC-1295 DAC is generally discussed as well tolerated when used conservatively, though higher doses may increase the chance of water retention, mild headache, temporary joint discomfort, increased appetite, or injection-site irritation.

Because the peptide can influence growth hormone and IGF-1 activity over an extended period, gradual protocol design is often preferred to help assess tolerance.

CJC-1295 DAC Contraindications/Precautionary Measures

CJC-1295 DAC should not be used by pregnant or nursing women. Individuals with a history of cancer, pituitary disorders, or serious endocrine issues should use caution due to the peptide's role in growth hormone signaling. Proper sterile handling and storage should always be followed. Keep out of reach of children.

Overdosage

Excessive dosing may increase the chance of water retention, headache, joint discomfort, numbness, or other GH-related side effects. Because CJC-1295 DAC is long acting, unwanted effects may persist longer than with short-acting peptides.

CJC-1295 DAC Stack/Cycle

CJC-1295 DAC is often researched alongside other peptides involved in growth hormone support and recovery-focused protocols. Common combinations include:

• MK-677 (Ibutamoren) – often explored in stacks centered on GH and IGF-1 support, recovery, and sleep quality
• Ipamorelin/Tesamorelin Blend – sometimes studied for combining shorter GH pulses with longer baseline peptide activity
• GHRP-6 – commonly paired in GH-related protocols where appetite and secretagogue support are also being researched

These combinations are typically explored by users interested in recovery, body composition support, sleep quality, and long-term GH-axis optimization.

Package Presentation

Dragon Pharma presents CJC-1295 DAC in a sterile 2 mL vial containing 5 mg of lyophilized powder. The freeze-dried format helps preserve stability before reconstitution and supports accurate dose preparation.

Storage

Store the lyophilized vial in a cool, dry place away from direct light and moisture, ideally at 2-8°C. After reconstitution with bacteriostatic water, keep refrigerated and use within 2-3 weeks for best stability. Do not freeze.

CJC-1295 DAC Referrers

This product is intended for laboratory research and analytical purposes only. Not for human consumption. Always verify the legality of this compound in your jurisdiction before purchase.

CJC-1295 DAC Frequently Asked Questions